Related Experiment Video
Updated: Oct 4, 2025

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
Published on: November 22, 2019
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Lina Merkens1, Verena Sailer2, Davor Lessel3
1Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. l.merkens@uke.de.
Abstract:
Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventually progresses to castration-resistant disease. To date, various mechanisms of resistance have been identified including the development of AR-independent aggressive variant prostate cancer based on neuroendocrine transdifferentiation (NED). Here, we review the highly complex processes contributing to NED. Genetic, epigenetic, transcriptional aberrations and posttranscriptional modifications are highlighted and the potential interplay of the different factors is discussed. Background Aggressive variant prostate cancer (AVPC) with traits of neuroendocrine differentiation emerges in a rising number of patients in recent years. Among others, advanced therapies targeting the androgen receptor axis have been considered causative for this development. Cell growth of AVPC often occurs completely independent of the androgen receptor signal transduction pathway and cells have mostly lost the typical cellular features of prostate adenocarcinoma. This complicates both diagnosis and treatment of this very aggressive disease. We believe that a deeper understanding of the complex molecular pathological mechanisms contributing to transdifferentiation will help to improve diagnostic procedures and develop effective treatment strategies. Indeed, in recent years, many scientists have made important contributions to unravel possible causes and mechanisms in the context of neuroendocrine transdifferentiation. However, the complexity of the diverse molecular pathways has not been captured completely, yet. This narrative review comprehensively highlights the individual steps of neuroendocrine transdifferentiation and makes an important contribution in bringing together the results found so far.
Insights
Aggressive variant prostate cancer can develop from hormone-driven prostate cancer through neuroendocrine transdifferentiation (NED). Understanding the complex molecular changes driving NED is crucial for new diagnostic and treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer is hormone-dependent, relying on androgen receptor (AR) signaling.
- Therapies targeting AR signaling can lead to castration-resistant disease.
- Aggressive variant prostate cancer (AVPC) with neuroendocrine differentiation (NED) is an emerging challenge.
Purpose of the Study:
- To review the complex molecular processes underlying neuroendocrine transdifferentiation (NED) in prostate cancer.
- To consolidate current understanding of the mechanisms driving aggressive variant prostate cancer (AVPC).
- To provide insights for improved diagnostics and therapeutics for AVPC.
Main Methods:
- This study is a narrative review.
- It synthesizes existing research on genetic, epigenetic, transcriptional, and posttranscriptional changes in NED.
- It discusses the interplay between these molecular factors.
Main Results:
- Neuroendocrine transdifferentiation (NED) involves complex genetic, epigenetic, and transcriptional alterations.
- These changes enable AR-independent growth characteristic of aggressive variant prostate cancer (AVPC).
- The interplay of these factors contributes to treatment resistance.
Conclusions:
- A comprehensive understanding of NED mechanisms is essential for advancing prostate cancer treatment.
- Further research into the molecular pathways of NED can guide the development of novel diagnostic and therapeutic strategies.
- Targeting NED may offer new avenues for managing aggressive variant prostate cancer.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...